Get the Stockscreener App
3.92
1.01%
-0.04
Bioharvest Sciences Inc stock is traded at $3.92, with a volume of 14,548.
It is down -1.01% in the last 24 hours and down -9.89% over the past month.
BioHarvest Sciences Inc is the developer and owner of the patented bio-cell growth platform farming technology. The Company has two operating segments or business units: the Products business unit and the CDMO Services business unit. In identifying these operating segments, management generally follows the Company's service lines representing its main products and services. The Products Business Unit - Nutraceuticals: Research, development, manufacturing, marketing and sales of science-based health and wellness nutraceutical solutions which are manufactured and sold as dietary supplements, functional food and beverages. The CDMO Services Business Unit - comprising a Contract Development and Manufacturing Operation that offers pharmaceuticals, cosmeceuticals, nutraceuticals, and nutritions.
See More
Previous Close:
$3.96
Open:
$4
24h Volume:
14,548
Relative Volume:
0.52
Market Cap:
$88.86M
Revenue:
$35.16M
Net Income/Loss:
$-11.44M
P/E Ratio:
-6.5761
EPS:
-0.5961
Net Cash Flow:
$-15.44M
1W Performance:
+2.08%
1M Performance:
-9.89%
6M Performance:
-37.88%
1Y Performance:
-39.60%
1-Day Range:
$3.91
$4.048
1-Week Range:
$3.76
$4.26
52-Week Range:
$3.57
$12.80
Bioharvest Sciences Inc Stock (BHST) Company Profile
Name
Bioharvest Sciences Inc
Sector
Industry
Phone
-
Address
-
Compare BHST vs KHC, GIS, JBS, MKC, HRL
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BHST
Bioharvest Sciences Inc
|
3.92 | 89.76M | 35.16M | -11.44M | -15.44M | -0.5961 |
KHC
Kraft Heinz Co
|
23.28 | 27.69B | 24.99B | -5.76B | 3.95B | -4.863 |
GIS
General Mills Inc
|
33.77 | 17.85B | 18.37B | 2.22B | 1.65B | 4.0676 |
JBS
Jbs Nv
|
12.49 | 13.77B | 66.64B | 1.80B | 773.23M | 1.7184 |
MKC
Mccormick Co Inc
|
47.25 | 12.55B | 7.11B | 1.65B | 680.40M | 6.1005 |
HRL
Hormel Foods Corp
|
20.40 | 11.21B | 12.14B | 489.00M | 577.53M | 0.8886 |
Bioharvest Sciences Inc Stock (BHST) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-19-26 | Initiated | Roth Capital | Buy |
| May-05-25 | Initiated | Craig Hallum | Buy |
| Dec-18-24 | Initiated | Maxim Group | Buy |
Bioharvest Sciences Inc Stock (BHST) Latest News
Bioharvest Sciences Signals Progress Amid Near-Term Losses - TipRanks
BioHarvest Sciences and Tate & Lyle expand sweetener development program - Proactive financial news
BioHarvest (BHST) Q1 2026 Earnings Transcript - AOL.com
BioHarvest expands Tate & Lyle sweetener development deal By Investing.com - Investing.com Australia
Tate & Lyle expands plant-based sweetener innovation partnership with BioHarvest Sciences - New Food
BioHarvest expands Tate & Lyle sweetener development deal - Investing.com
Tate & Lyle Expands Collaboration with BioHarvest Sciences to Accelerate Next-Generation Sweetener Innovation - TMX Newsfile
New plant-based sweeteners aim to cut sugar in more foods - Stock Titan
BioHarvest Sciences Q1 earnings call highlights - MSN
BioHarvest outlines 2026 revenue of $38M-$42M in D2C and $12M-$14M in CDMO activity while targeting 2H 2027 fragrance production - MSN
H.C. Wainwright Maintains BioHarvest Sciences(BHST.US) With Buy Rating, Maintains Target Price $14 - Moomoo
BioHarvest Sciences Inc. Common Stock Q1 2026 Earnings Call Summary - Yahoo Finance
BioHarvest Sciences Inc (BHST) Q1 2026 Earnings Call Highlights: Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
BioHarvest Sciences Inc (BHST) Q1 2026 Earnings Call Highlights: - GuruFocus
BioHarvest Sciences (NASDAQ:BHST) Announces Quarterly Earnings Results - MarketBeat
BioHarvest Sciences Inc. (BHST) reports Q4 loss, lags revenue estimates - MSN
BioHarvest Sciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
BioHarvest Sciences Posts Q1 2026 Growth and Advances Botanical Synthesis Deals - TipRanks
BioHarvest Sciences: Q1 revenue up 8% YoY, CDMO revenue up 135%, net loss at $2.6M, gross margin at 59% - TradingView
BioHarvest Sciences (NASDAQ: BHST) posts Q1 2026 growth with $8.5M revenue - Stock Titan
Small cap wrap: VivoPower, BioHarvest Sciences, Phunware, Tiziana Life Sciences… - Proactive financial news
BioHarvest Sciences Files Q1 2026 Financials on Form 6-K - TipRanks
BioHarvest Sciences Q1 2026 Earnings Call Transcript - MarketBeat
BioHarvest Sciences (NASDAQ: BHST) grows Q1 2026 revenue while warning on going concern - Stock Titan
BioHarvest Sciences Names New Business Development Chief to Drive CDMO Growth - TipRanks
BioHarvest Sciences: Q1 revenue up 8% to $8.5M, CDMO and D2C segments advance, 2026 outlook reaffirmed - TradingView
New CDMO business development leader joins BioHarvest Sciences (NASDAQ: BHST) - Stock Titan
BioHarvest Sciences Q1 Earnings Call Highlights - MarketBeat
BioHarvest Sciences: Q1 2026 revenue up 8% to $8.5M; key CDMO and D2C milestones achieved; cash at $20.2M - TradingView
BioHarvest Sciences Inc. (BHST) reports Q1 loss, beats revenue estimates - MSN
BioHarvest Sciences Q1 revenue climbs as it expands botanical synthesis pipeline - Proactive financial news
BioHarvest Sciences : First Quarter 2026 Financial Statements - marketscreener.com
BioHarvest Sciences Inc. (BHST) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
BioHarvest Sciences: Q1 revenue up 8% year-over-year, driven by CDMO and VINIA growth; net loss at $2.6 million - TradingView
BioHarvest Sciences Reports First Quarter 2026 Financial Results and Provides Business Update - TradingView
BioHarvest Sciences produces active plant ingredients without growing the plant itself - Proactive financial news
BioHarvest appoints Salzman-Frenkel as VP business development - Investing.com UK
BioHarvest appoints Salzman-Frenkel as VP business development By Investing.com - Investing.com Nigeria
She closed $30M in drug contracts; now she’ll hunt CDMO deals for BioHarvest - Stock Titan
Small cap wrap: TNR Gold, Power Metallic Mines, BioHarvest Sciences, Midnight Sun Mining… - Proactive financial news
BioHarvest Advances Saffron CDMO Program to Stage 2 After Completing Cell Bank Milestone - TipRanks
BioHarvest Sciences (NASDAQ: BHST) completes Stage 1 in $1.125M saffron deal - Stock Titan
BioHarvest advances saffron cell bank project to stage 2 By Investing.com - Investing.com India
BioHarvest Sciences advances synthetic saffron program with SaffronTech partnership - Proactive financial news
BioHarvest advances saffron cell bank project to stage 2 - Investing.com UK
$1.125M saffron cell project aims at sustainable health and flavor - Stock Titan
BioHarvest secures $1.2M fragrance development contract By Investing.com - Investing.com Australia
BioHarvest Sciences Installs Co-Founder Zaki Rakib as CEO in Strategic Leadership Shift - The Globe and Mail
BioHarvest Sciences Secures $1.2M Stage 2 CDMO Deal for Rare Fragrance Development - TipRanks
BioHarvest Sciences Signs $1.2 Mln CDMO Stage 2 Contract - TradingView
BioHarvest Sciences (NASDAQ: BHST) lands $1.2M Stage 2 rare fragrance deal - Stock Titan
Bioharvest Sciences Inc Stock (BHST) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
1.59%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):